European Union

Outlook Therapeutics Limited

Reference: 727775

Open in El Vínculo

3

Awards

€221,000

Total awarded

Contact

Email: janinesubert@outlooktherapeutics.com
Phone: +4915758725517

Recent awards

Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V Lytenava(R) Wirkstoff: Bevacizumab gamma ATC-Code: S01LA08
Vereinbarung nach § 130a Abs. 8 SGB V i. V. m. § 130c Abs. 1 SGB V zum Wirkstoff Bevacizumab gamma (Lytenava™)
· €221,000

Get alerts for tenders like this
Create a free account and receive new tenders from European Union matching your business, every day.

Data collected from official public procurement sources. Amounts as published by the buyer.